EntryPoint Capital LLC Trims Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

EntryPoint Capital LLC cut its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 19.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,908 shares of the company’s stock after selling 941 shares during the quarter. EntryPoint Capital LLC’s holdings in Harmony Biosciences were worth $131,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in HRMY. UniSuper Management Pty Ltd acquired a new stake in shares of Harmony Biosciences in the first quarter valued at $389,000. Hillsdale Investment Management Inc. grew its stake in Harmony Biosciences by 8.9% during the 1st quarter. Hillsdale Investment Management Inc. now owns 69,600 shares of the company’s stock worth $2,337,000 after purchasing an additional 5,700 shares in the last quarter. Edgestream Partners L.P. increased its holdings in Harmony Biosciences by 23.2% during the 1st quarter. Edgestream Partners L.P. now owns 60,281 shares of the company’s stock worth $2,024,000 after purchasing an additional 11,336 shares during the period. Capital Management Corp VA acquired a new stake in Harmony Biosciences in the 1st quarter valued at about $7,018,000. Finally, ProShare Advisors LLC increased its stake in shares of Harmony Biosciences by 7.0% during the first quarter. ProShare Advisors LLC now owns 10,488 shares of the company’s stock worth $352,000 after buying an additional 684 shares during the period. 86.23% of the stock is owned by hedge funds and other institutional investors.

Harmony Biosciences Trading Up 0.1 %

Shares of Harmony Biosciences stock traded up $0.02 during trading on Friday, reaching $33.32. 58,111 shares of the company were exchanged, compared to its average volume of 384,741. The business has a 50-day moving average price of $30.87 and a 200-day moving average price of $31.29. The company has a quick ratio of 3.07, a current ratio of 3.11 and a debt-to-equity ratio of 0.34. The firm has a market capitalization of $1.89 billion, a price-to-earnings ratio of 14.42, a P/E/G ratio of 0.72 and a beta of 0.72. Harmony Biosciences Holdings, Inc. has a twelve month low of $18.61 and a twelve month high of $39.26.

Harmony Biosciences (NASDAQ:HRMY) last released its earnings results on Tuesday, April 30th. The company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.07. The business had revenue of $154.62 million for the quarter, compared to analyst estimates of $154.10 million. Harmony Biosciences had a return on equity of 28.26% and a net margin of 22.30%. Harmony Biosciences’s revenue was up 29.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.48 earnings per share. Sell-side analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.02 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Citigroup started coverage on Harmony Biosciences in a report on Friday, June 21st. They issued a “buy” rating and a $48.00 target price on the stock. Needham & Company LLC restated a “buy” rating and set a $52.00 target price on shares of Harmony Biosciences in a research report on Monday, June 24th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $49.00 price objective on shares of Harmony Biosciences in a research report on Friday, April 12th. Two investment analysts have rated the stock with a sell rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $41.67.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.